Effect of alfacalcidol on cardiac function in patients with chronic kidney disease stage 4 and secondary hyperparathyroidism: A pilot study

Scandinavian Journal of Urology and Nephrology

Volumn 46, Issue 5, 2012, Pages 381-388

  Ivarsen, Per ^a   Povlsen, Johan Vestergaard ^a   Christensen, Kent Lodberg ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Alfacalcidol; Chronic kidney disease; Hyperparathyroidism; Left ventricular function; Vitamin D.

Indexed keywords

ALDOSTERONE; ALFACALCIDOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM ION; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PARATHYROID HORMONE; RENIN; VITAMIN D RECEPTOR;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFECT; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; IMAGING SYSTEM; MALE; OPEN STUDY; PARATHYROID HORMONE BLOOD LEVEL; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME; VITAMIN D DEFICIENCY;

ADULT; AGED; BONE DENSITY CONSERVATION AGENTS; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPERPARATHYROIDISM, SECONDARY; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PILOT PROJECTS; RENAL INSUFFICIENCY, CHRONIC; VENTRICULAR DYSFUNCTION, LEFT; VITAMIN D DEFICIENCY;

EID: 84866554258     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.3109/00365599.2012.693131     Document Type: Article

References (35)

1. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar- Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008;168:397-403. (Pubitemid 351350586)
2. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008;19: 1613-19.
3. Cozzolino M, Ketteler M, Zehnder D. The vitamin D system: A crosstalk between the heart and kidney. Eur J Heart Fail 2010;12:1031-41.
4. London GM, Parfrey PS. Cardiac disease in chronic uremia: Pathogenesis. Adv Ren Replace Ther 1997;4:194-211. (Pubitemid 27304995)
5. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-34. (Pubitemid 29318806)
6. Taddei S, Nami R, Bruno RM, Quatrini I, Nuti R. Hypertension, left ventricular hypertrophy and chronic kidney disease. Heart Fail Rev 2011;16:615-20.
7. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-8. (Pubitemid 44967731)
8. Shastri S, Sarnak MJ. Cardiovascular disease and CKD: Core curriculum 2010. Am J Kidney Dis 2010;56:399-417.
9. Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996;97:1577-88. (Pubitemid 26105467)
10. Rahman A, Hershey S, Ahmed S, Nibbelink K, Simpson RU. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J Steroid Biochem Mol Biol 2007;103:416-19. (Pubitemid 46415673)
11. Weishaar RE, Simpson RU. Involvement of vitamin D3 with cardiovascular function. II. Direct and indirect effects. Am J Physiol 1987;253:E675-83.
12. Cotterill AM, Holly JM, Wass JA. The regulation of insulinlike growth factor binding protein (IGFBP)-1 during prolonged fasting. Clin Endocrinol (Oxf) 1993;39:357-62. (Pubitemid 23274436)
13. Koleganova N, Piecha G, Ritz E, Gross ML. Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrectomized rats. Nephrol Dial Transplant 2009;24:778-87.
14. Mancuso P, Rahman A, Hershey SD, Dandu L, Nibbelink KA, Simpson RU. 1,25-Dihydroxyvitamin-D3 treatment reduces cardiac hypertrophy and left ventricular diameter in spontaneously hypertensive heart failure-prone (cp/+) rats independent of changes in serum leptin. J Cardiovasc Pharmacol 2008;51:559-64.
15. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, et al. Activated vitaminDattenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 2007;104:16810-15. (Pubitemid 350210947)
16. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999;33:73-81.
17. Kim HW, Park CW, Shin YS, Kim YS, Shin SJ, Kim YS, et al. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract 2006;102:c21-9.
18. Lemmila S, Saha H, Virtanen V, Ala-Houhala I, Pasternack A. Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis. Am J Nephrol 1998;18:404-10. (Pubitemid 28442103)
19. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the rennin-angiotensin system. J Clin Invest 2002;110: 229-38. (Pubitemid 34787360)
20. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: Role of the systemic and cardiac rennin- angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288:E125-32. (Pubitemid 40023798)
21. Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007;103: 521-4. (Pubitemid 46420533)
22. Resnick LM. Calciotropic hormones in salt-sensitive essential hypertension: 1,25-dihydroxyvitamin D and parathyroid hypertensive factor. J Hypertens Suppl 1994;12:S3-9.
23. Christensen KL, Fenger-Gron M, Buus NH. Echocardiography of left ventricular mass in patients with essential hypertension. Ugeskr Laeger 2009;171:3252-5.
24. Bruch C, Schmermund A, Dagres N, Katz M, Bartel T, Erbel R. Tei-index in coronary artery disease - validation in patients with overall cardiac and isolated diastolic dysfunction. Z Kardiol 2002;91:472-80. (Pubitemid 34713116)
25. Kong J, Kim GH, Wei M, Sun T, Li G, Liu SQ, et al. Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Am J Pathol 2010; 177:622-31.
26. Lang RM, Fellner SK, Neumann A, Bushinsky DA, Borow KM. Left ventricular contractility varies directly with blood ionized calcium. Ann Intern Med 1988;108: 524-9.
27. Dujardin KS, Tei C, Yeo TC, Hodge DO, Rossi A, Seward JB. Prognostic value of a Doppler index combining systolic and diastolic performance in idiopathic-dilated cardiomyopathy. Am J Cardiol 1998;82:1071-6. (Pubitemid 28507090)
28. Lakoumentas JA, Panou FK, Kotseroglou VK, Aggeli KI, Harbis PK. The Tei index of myocardial performance: Applications in cardiology. Hellenic J Cardiol 2005;46:52-8. (Pubitemid 41657714)
29. Moe SM, Saifullah A, LaClair RE, Usman SA, Yu Z. A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clin J Am Soc Nephrol 2010;5:299-306.
30. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: A double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006;83:754-9. (Pubitemid 44713136)
31. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA 2012;307:674-84.
32. Koleganova N, Piecha G, Ritz E, Bekeredjian R, Schirmacher P, Schmitt CP, et al. Interstitial fibrosis and microvascular disease of the heart in uremia: Amelioration by a calcimimetic. Lab Invest 2009;89:520-30.
33. Covic A, Voroneanu L, Goldsmith D. The effects of vitamin D therapy on left ventricular structure and function - are these the underlying explanations for improved CKD patient survival? Nephron Clin Pract 2010;116:c187-95.
34. Eckardt KU, Scherhag A, Macdougall IC, Tsakiris D, Clyne N, Locatelli F, et al. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J Am Soc Nephrol 2009;20:2651-60.
35. Pappas KD, Gouva CD, Katopodis KP, Nikolopoulos PM, Korantzopoulos PG, Michalis LK, et al. Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): Effects on cardiac performance. Cardiovasc Drugs Ther 2008;22:37-44